Home - Clinical Trials Arena
Zepbound will dominate obesity market following SURMOUNT-5 results, says analyst. According to key opinion leaders, positive SURMOUNT-5 results, alongside Lilly’s business strategy, means Zepbound is set to overtake competitors.
IDWeek 2024: Moderna’s norovirus vaccine mRNA-1403 shows …
Oct 21, 2024 · At IDWeek 2024, Moderna presented interim results from an ongoing Phase I/II, randomised, observer-blind, placebo-controlled, dose-ranging trial (NCT05992935) for mRNA-1403, a prophylactic vaccine candidate under investigation for norovirus (NoV) infections. As one of the leading causes of acute gastroenteritis worldwide, NoV is associated with a substantial healthcare burden.
Lebrikizumab, Tralokinumab and Dupilumab compete in AD space
Oct 8, 2024 · Lebrikizumab, tralokinumab and dupilumab to compete in atopic dermatitis space. The separation of Ebglyss from Dupixent and Adbry/Adtralza will depend on real-world clinical benefits, patient experience and cost-effectiveness.
MILOS study: The real-world use of bempedoic acid
Oct 4, 2024 · Daiichi Sankyo has announced the final two-year follow-up data from the German cohort of the MILOS study. The MILOS study is a real-world investigation into the use of bempedoic acid for managing high cholesterol levels. Bempedoic acid and its fixed-dose combination with ezetimibe, with or without other lipid therapies, has been shown to significantly reduce low-density lipoprotein cholesterol ...
Sound Pharmaceuticals concludes Phase III Meniere’s disease trial
Aug 1, 2024 · The study is now in the RCT data analysis stage with interim topline results anticipated to be presented this quarter. The STOPMD-3 study began subject randomisation in August 2022 and concluded with the last patient visit on 25 July 2024.
GSK ceases HSV vaccine - a chance for Moderna and BioNTech
Sep 25, 2024 · GSK recently announced the discontinuation of its herpes simplex virus (HSV) therapeutic vaccine candidate, GSK3943104, following the failure of a Phase I/II clinical trial to meet its primary efficacy goals.. The vaccine aimed to reduce lesions in patients with recurrent genital herpes – a high unmet medical need. Although deemed safe, its lack of efficacy led to GSK’s decision not to ...
AHA 2024: semaglutide continues to impress in diabetic kidney …
In March 2024, Novo announced positive results from the kidney outcomes trial FLOW. According to the trial, semaglutide 1.0mg reduced risk of kidney disease progression and the risk of kidney and cardiovascular deaths by 24%.
MHRA expects new UK clinical trial regulation implementation by …
Oct 16, 2024 · Between 2022 and 2023, the MHRA undertook a consultation period surrounding a new legislative framework for clinical trials in the UK. The MHRA said the new regulation will ensure patients and their safety are the focus of all clinical trials, while bringing the benefits of clinical trials to everyone.
Newsletters - Clinical Trials Arena
Explore our marketing solutions. Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Phase 0 clinical trials: what you need to know
Jul 21, 2022 · Traditional Phase 0s reveal more data earlier. In a Phase 0 trial, sponsors can more quickly learn about a drug’s pharmacokinetics (PK) in humans with reduced manufacturing and toxicology costs, explains Phase 0 consultant Dr Tal Burt.